New hope for rare HIV-2: study tests raltegravir combo
NCT ID NCT01605890
First seen Apr 05, 2026 · Last updated May 20, 2026 · Updated 8 times
Summary
This study tested a new first-line treatment for HIV-2, a less common form of HIV. Thirty participants who had never taken HIV medication received a combination of raltegravir, emtricitabine, and tenofovir. The goal was to see if this combination could control the virus and improve immune cell counts better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV 2 INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Bichat-Claude Bernard
Paris, 75018, France
Conditions
Explore the condition pages connected to this study.